Antiretroviral Drugs Promote Amyloidogenesis by De-Acidifying Endolysosomes

Liang Hui, Yan Ye, Mahmoud L. Soliman, Koffi L. Lakpa, Nicole M. Miller, Zahra Afghah, Jonathan D. Geiger, Xuesong Chen

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Antiretroviral therapeutics (ART) have effectively increased the long-term survival of HIV-1 infected individuals. However, the prevalence of HIV-1 associated neurocognitive disorders (HAND) has increased and so too have clinical manifestations and pathological features of Alzheimer’s disease (AD) in people living with HIV-1/AIDS. Although underlying mechanisms are not clear, chronic exposure to ART drugs has been implicated in the development of AD-like symptoms and pathology. ART drugs are categorized according to their mechanism of action in controlling HIV-1 levels. All ART drugs are organic compounds that can be classified as being either weak acids or weak bases, and these physicochemical properties may be of central importance to ART drug-induced AD-like pathology because weak bases accumulate in endolysosomes, weak bases can de-acidify endolysosomes where amyloidogenesis occurs, and endolysosome de-acidification increases amyloid beta (Aβ) protein production and decreases Aβ degradation. Here, we investigated the effects of ART drugs on endolysosome pH and Aβ levels in rat primary cultured neurons. ART drugs that de-acidified endolysosomes increased Aβ levels, whereas those that acidified endolysosomes decreased Aβ levels. Acidification of endolysosomes with the mucolipin transient receptor potential (TRPML) channel agonist ML-SA1 blocked ART drug-induced increases in Aβ levels. Further, ART drug-induced endolysosome de-acidification increased endolysosome sizes; effects that were blocked by ML-SA1-induced endolysosome acidification. These results suggest that ART drug-induced endolysosome de-acidification plays an important role in ART drug-induced amyloidogenesis and that endolysosome acidification might attenuate AD-like pathology in HIV-1 positive people taking ART drugs that de-acidify endolysosomes. [Figure not available: see fulltext.].

Original languageEnglish (US)
JournalJournal of Neuroimmune Pharmacology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Pharmaceutical Preparations
HIV-1
Alzheimer Disease
Therapeutics
Pathology
Transient Receptor Potential Channels
Serum Amyloid A Protein
Amyloid beta-Peptides
Therapeutic Uses
Acquired Immunodeficiency Syndrome
Neurons
Acids

Keywords

  • Alzheimer’s disease
  • Amyloid beta
  • Antiretroviral therapy
  • Endolysosome pH

ASJC Scopus subject areas

  • Neuroscience (miscellaneous)
  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Antiretroviral Drugs Promote Amyloidogenesis by De-Acidifying Endolysosomes. / Hui, Liang; Ye, Yan; Soliman, Mahmoud L.; Lakpa, Koffi L.; Miller, Nicole M.; Afghah, Zahra; Geiger, Jonathan D.; Chen, Xuesong.

In: Journal of Neuroimmune Pharmacology, 01.01.2019.

Research output: Contribution to journalArticle

Hui, Liang ; Ye, Yan ; Soliman, Mahmoud L. ; Lakpa, Koffi L. ; Miller, Nicole M. ; Afghah, Zahra ; Geiger, Jonathan D. ; Chen, Xuesong. / Antiretroviral Drugs Promote Amyloidogenesis by De-Acidifying Endolysosomes. In: Journal of Neuroimmune Pharmacology. 2019.
@article{a0b8fe958a7d4ba49a15da4a1600e5f9,
title = "Antiretroviral Drugs Promote Amyloidogenesis by De-Acidifying Endolysosomes",
abstract = "Antiretroviral therapeutics (ART) have effectively increased the long-term survival of HIV-1 infected individuals. However, the prevalence of HIV-1 associated neurocognitive disorders (HAND) has increased and so too have clinical manifestations and pathological features of Alzheimer’s disease (AD) in people living with HIV-1/AIDS. Although underlying mechanisms are not clear, chronic exposure to ART drugs has been implicated in the development of AD-like symptoms and pathology. ART drugs are categorized according to their mechanism of action in controlling HIV-1 levels. All ART drugs are organic compounds that can be classified as being either weak acids or weak bases, and these physicochemical properties may be of central importance to ART drug-induced AD-like pathology because weak bases accumulate in endolysosomes, weak bases can de-acidify endolysosomes where amyloidogenesis occurs, and endolysosome de-acidification increases amyloid beta (Aβ) protein production and decreases Aβ degradation. Here, we investigated the effects of ART drugs on endolysosome pH and Aβ levels in rat primary cultured neurons. ART drugs that de-acidified endolysosomes increased Aβ levels, whereas those that acidified endolysosomes decreased Aβ levels. Acidification of endolysosomes with the mucolipin transient receptor potential (TRPML) channel agonist ML-SA1 blocked ART drug-induced increases in Aβ levels. Further, ART drug-induced endolysosome de-acidification increased endolysosome sizes; effects that were blocked by ML-SA1-induced endolysosome acidification. These results suggest that ART drug-induced endolysosome de-acidification plays an important role in ART drug-induced amyloidogenesis and that endolysosome acidification might attenuate AD-like pathology in HIV-1 positive people taking ART drugs that de-acidify endolysosomes. [Figure not available: see fulltext.].",
keywords = "Alzheimer’s disease, Amyloid beta, Antiretroviral therapy, Endolysosome pH",
author = "Liang Hui and Yan Ye and Soliman, {Mahmoud L.} and Lakpa, {Koffi L.} and Miller, {Nicole M.} and Zahra Afghah and Geiger, {Jonathan D.} and Xuesong Chen",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s11481-019-09862-1",
language = "English (US)",
journal = "Journal of NeuroImmune Pharmacology",
issn = "1557-1890",
publisher = "Springer New York",

}

TY - JOUR

T1 - Antiretroviral Drugs Promote Amyloidogenesis by De-Acidifying Endolysosomes

AU - Hui, Liang

AU - Ye, Yan

AU - Soliman, Mahmoud L.

AU - Lakpa, Koffi L.

AU - Miller, Nicole M.

AU - Afghah, Zahra

AU - Geiger, Jonathan D.

AU - Chen, Xuesong

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Antiretroviral therapeutics (ART) have effectively increased the long-term survival of HIV-1 infected individuals. However, the prevalence of HIV-1 associated neurocognitive disorders (HAND) has increased and so too have clinical manifestations and pathological features of Alzheimer’s disease (AD) in people living with HIV-1/AIDS. Although underlying mechanisms are not clear, chronic exposure to ART drugs has been implicated in the development of AD-like symptoms and pathology. ART drugs are categorized according to their mechanism of action in controlling HIV-1 levels. All ART drugs are organic compounds that can be classified as being either weak acids or weak bases, and these physicochemical properties may be of central importance to ART drug-induced AD-like pathology because weak bases accumulate in endolysosomes, weak bases can de-acidify endolysosomes where amyloidogenesis occurs, and endolysosome de-acidification increases amyloid beta (Aβ) protein production and decreases Aβ degradation. Here, we investigated the effects of ART drugs on endolysosome pH and Aβ levels in rat primary cultured neurons. ART drugs that de-acidified endolysosomes increased Aβ levels, whereas those that acidified endolysosomes decreased Aβ levels. Acidification of endolysosomes with the mucolipin transient receptor potential (TRPML) channel agonist ML-SA1 blocked ART drug-induced increases in Aβ levels. Further, ART drug-induced endolysosome de-acidification increased endolysosome sizes; effects that were blocked by ML-SA1-induced endolysosome acidification. These results suggest that ART drug-induced endolysosome de-acidification plays an important role in ART drug-induced amyloidogenesis and that endolysosome acidification might attenuate AD-like pathology in HIV-1 positive people taking ART drugs that de-acidify endolysosomes. [Figure not available: see fulltext.].

AB - Antiretroviral therapeutics (ART) have effectively increased the long-term survival of HIV-1 infected individuals. However, the prevalence of HIV-1 associated neurocognitive disorders (HAND) has increased and so too have clinical manifestations and pathological features of Alzheimer’s disease (AD) in people living with HIV-1/AIDS. Although underlying mechanisms are not clear, chronic exposure to ART drugs has been implicated in the development of AD-like symptoms and pathology. ART drugs are categorized according to their mechanism of action in controlling HIV-1 levels. All ART drugs are organic compounds that can be classified as being either weak acids or weak bases, and these physicochemical properties may be of central importance to ART drug-induced AD-like pathology because weak bases accumulate in endolysosomes, weak bases can de-acidify endolysosomes where amyloidogenesis occurs, and endolysosome de-acidification increases amyloid beta (Aβ) protein production and decreases Aβ degradation. Here, we investigated the effects of ART drugs on endolysosome pH and Aβ levels in rat primary cultured neurons. ART drugs that de-acidified endolysosomes increased Aβ levels, whereas those that acidified endolysosomes decreased Aβ levels. Acidification of endolysosomes with the mucolipin transient receptor potential (TRPML) channel agonist ML-SA1 blocked ART drug-induced increases in Aβ levels. Further, ART drug-induced endolysosome de-acidification increased endolysosome sizes; effects that were blocked by ML-SA1-induced endolysosome acidification. These results suggest that ART drug-induced endolysosome de-acidification plays an important role in ART drug-induced amyloidogenesis and that endolysosome acidification might attenuate AD-like pathology in HIV-1 positive people taking ART drugs that de-acidify endolysosomes. [Figure not available: see fulltext.].

KW - Alzheimer’s disease

KW - Amyloid beta

KW - Antiretroviral therapy

KW - Endolysosome pH

UR - http://www.scopus.com/inward/record.url?scp=85069490415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069490415&partnerID=8YFLogxK

U2 - 10.1007/s11481-019-09862-1

DO - 10.1007/s11481-019-09862-1

M3 - Article

C2 - 31338753

AN - SCOPUS:85069490415

JO - Journal of NeuroImmune Pharmacology

JF - Journal of NeuroImmune Pharmacology

SN - 1557-1890

ER -